Case: Perrigo Company plc
Contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

NEW YORK, NY – January 2, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased Perrigo Company plc (“Perrigo”) (NYSE: PRGO) securities.  Perrigo is a global healthcare company that is headquartered in Ireland, and sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China.  

In April 2013, Elan Pharma International Limited (“Elan Pharma”) (n/k/a Perrigo Pharma International) sold certain intellectual property for the drug Tysabri and related assets to Biogen Inc. (“Biogen”).  The consideration paid by Biogen took the form of an upfront payment and future contingent payments.  Perrigo acquired Elan Pharma through a December 2013 business combination between Perrigo’s predecessor and Elan Corporation, plc. 

On December 20, 2018, Perrigo filed a report with the U.S. Securities and Exchange Commission that disclosed that Perrigo Pharma International received a Notice of Amended Assessment (“NOA”) issued by the Irish Office of the Revenue Commissions that assesses a tax liability against Elan Pharma in the amount of approximately €1.64 billion (approximately $1.86 billion), not including interest or penalties.  The Irish Office of the Revenue Commissioners found that Elan Pharma had paid an incorrect tax rate - 12.5% instead of 33% - on proceeds from the 2013 sale of intellectual property to Biogen. 

On December 20, 2018, Perrigo shares declined $15.33 per share, or approximately 30%, to close at $37.03 per share.

If you are an investor in Perrigo and would like to discuss our investigation, please contact us by emailing This e-mail address is being protected from spambots. You need JavaScript enabled to view it or by calling 800-290-1952.  

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.  If you have any questions about this Notice, the action, your rights, or your interests, please contact: 

Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(800) 290-1952
(212) 687-1980
Fax: (212) 687-7714
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
350 Sansome Street, Suite 400 
San Francisco, California  94104
(415) 772-4700
Fax:  (415) 772-4707
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it